American Well Corporation ((AMWL)) has held its Q1 earnings call. Read on for the main highlights of the call.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
American Well Corporation’s latest earnings call struck a cautiously optimistic tone, as management balanced sharp cost improvements and a better path to profitability against continued revenue and usage declines. Executives emphasized improved adjusted EBITDA, a higher-quality visit mix, strong renewals, and robust cash reserves, while acknowledging that the company remains loss-making and faces near‑term top‑line pressure.
Profitability Turns a Corner Despite Revenue Pressure
Adjusted EBITDA loss narrowed to $3.1 million in Q1 2026 from $12.2 million a year earlier, marking a $9.1 million improvement. Operating loss shrank roughly 43% to $17.4 million from $30.4 million, underscoring that Amwell’s restructuring and efficiency measures are materially improving its profitability trajectory even as revenue falls.
Sharp Cut in 2025 Losses Signals Structural Change
Management highlighted that net loss and adjusted EBITDA losses in 2025 were reduced by about $100 million, reflecting deep cost and operational changes rather than one‑off items. Investors are likely to see this as evidence that Amwell’s business model is becoming more sustainable, with the company moving closer to breakeven even without strong growth.
Higher-Value Virtual Care Mix Gains Traction
Amwell Medical Group revenue grew about 9% year over year to $28.9 million, with paid visits ticking up to roughly 382,000 and revenue per visit rising about $5 to $76. Virtual primary care visits surged around 57% year over year, indicating that demand is gravitating toward higher-acuity, higher‑value services that can support better unit economics over time.
Subscription Mix Builds Recurring Revenue Base
Subscription revenue accounted for roughly 53% of total revenue, increasing the recurring portion of the business even as dollars declined. The company reported renewals and retention ahead of budget, including a three‑year renewal with Elevance Health, which serves as a major validation of Amwell’s platform among large payers.
Cash Reserves and Burn Support Breakeven Path
Amwell ended the quarter with about $179 million in cash and investments and no debt, giving it significant financial flexibility. Quarterly cash burn fell sharply to roughly $3.1 million from $19 million in the prior period, bolstering management’s confidence in reaching operating cash flow breakeven by the fourth quarter of 2026 without needing additional capital.
Pipeline Expansion and Government Wins Add Credibility
The company reported that its sales pipeline is now a multiple of last year’s level, with the CFO suggesting growth approaching triple digits. Deployments with the Defense Health Agency and an extension within the military health system provide large‑scale government validation, and management expects a key DHA renewal decision around late Q2 or early Q3.
Lean Cost Structure Improves Operating Leverage
Total operating expenses fell about 31% year over year, and operating costs dropped to 82.6% of revenue versus 98.3% in Q1 2025. This tighter cost base gives Amwell more operating leverage, meaning that even modest revenue stabilization or growth could translate into faster margin improvement and a quicker path toward profitability.
Revenue Contraction Highlights Growth Challenges
Total Q1 2026 revenue declined roughly 18% year over year to $54.9 million, as management continued to exit or reshape parts of the portfolio and absorb earlier client churn. The top‑line pressure underscores that Amwell’s turnaround is being driven more by efficiency and mix rather than growth, leaving investors watching closely for any inflection in demand.
Subscription Revenue and Churn Weigh on Top Line
Subscription revenue fell about 23% year over year to $24.9 million, largely due to previously disclosed churn and portfolio changes, even though Q1 renewals beat internal expectations. Management noted that overall churn is now in the low single digits, but the company still faces customer concentration risks, particularly around large accounts such as Elevance and the timing of government expansions.
Platform Usage Decline Masks Strength in Premium Services
Total platform visits slid around 19% year over year to approximately 1.0 million, reflecting the same portfolio shifts that pressured revenue. Within that softer volume picture, however, Amwell saw growth in Amwell Medical Group and higher‑acuity segments, suggesting it is deliberately prioritizing quality and economics of visits over pure volume.
Margins Compress Slightly on Mix, Stabilization Expected
Gross profit came in at $28 million with a gross margin of 51.0%, down about 180 basis points from 52.8% a year earlier. Management indicated that near‑term revenue mix will likely keep margins around current levels, implying that any major margin expansion may depend on renewed growth in higher‑margin services and platform utilization.
Profitability Still Elusive Under Adjusted EBITDA Guidance
Amwell guided full‑year 2026 adjusted EBITDA to a loss of $16 million to $12 million, an improvement from the prior range of a $24 million to $18 million loss. For Q2 2026, management expects an adjusted EBITDA loss of $4 million to $2 million, confirming that while losses are narrowing, the company does not expect to reach profitability this year on that metric.
Forward-Looking Outlook and Management Guidance
For Q2 2026, Amwell forecast revenue of $48 million to $52 million and reiterated full‑year 2026 revenue of $195 million to $205 million, acknowledging normal seasonality and a step‑down in subscription revenue. Management maintained guidance for significantly reduced adjusted EBITDA losses and reiterated its goal of achieving positive operating cash flow in the fourth quarter, basing this confidence on Q1’s improved margins, lower cash burn, and strengthened visit mix.
Amwell’s earnings call painted the picture of a telehealth company in transition, trading growth for discipline as it works toward sustainable profitability. While revenue and usage remain under pressure and concentration risks linger, the combination of a leaner cost structure, improving unit economics, solid renewals, and ample cash leaves investors with an overall constructive, though still cautious, outlook on the turnaround story.